The fourth edition of the Art Bengaluru Collective is a multimedia, interactive affair thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity.
Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.